RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Background Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries. Methods RBD-specific antibody titres, as a rapidly available and highly predictive surrogat...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMC infectious diseases Ročník 22; číslo 1; s. 87 - 11
Hlavní autoři:	Ferenci, Tamás, Sarkadi, Balázs
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 24.01.2022 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Accreditation Age Aged Antibodies Antibody Formation Antibody response BBIBP-CorV Beijing Coronaviruses COVID-19 COVID-19 vaccines Disease Humans Infections Infectious Diseases Internal Medicine Laboratories Medical Microbiology Medicine Medicine & Public Health Older people Parasitology SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Sex Statistical analysis Testing Tropical Medicine Vaccination Vaccine Vaccines Viral antibodies Viral diseases Beijing Hungary Beijing China China COVID-19 SARS-CoV-2 Vaccine BBIBP-CorV Antibody response
ISSN:	1471-2334, 1471-2334
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!